Literature DB >> 23609016

Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.

Tim Heinrich1, Benjamin Rengstl, Alexander Muik, Mina Petkova, Frederike Schmid, Robin Wistinghausen, Kathrin Warner, Giuliano Crispatzu, Martin-Leo Hansmann, Marco Herling, Dorothee von Laer, Sebastian Newrzela.   

Abstract

Retroviral vectors (RVs) are powerful tools in clinical gene therapy. However, stable genomic integration of RVs can be oncogenic, as reported in several animal models and in clinical trials. Previously, we observed that T-cell receptor (TCR) polyclonal mature T cells are resistant to transformation after gammaretroviral transfer of (proto-)oncogenes, whereas TCR-oligoclonal T cells were transformable in the same setting. Here, we describe the induction of a mature T-cell lymphoma (MTCL) in TCR-oligoclonal OT-I transgenic T cells, transduced with an enhanced green fluorescent protein (EGFP)-encoding gammaretroviral vector. The tumor cells were of a mature T-cell phenotype and serially transplantable. Integration site analysis revealed a proviral hit in Janus kinase 1 (Jak1), which resulted in Jak1 overexpression and Jak/STAT-pathway activation, particularly via signal transducer and activator of transcription 3 (STAT3). Specific inhibition of Jak1 markedly delayed tumor growth. A systematic meta-analysis of available gene expression data on human mature T-cell lymphomas/leukemias confirmed the relevance of Jak/STAT overexpression in sporadic human T-cell tumorigenesis. To our knowledge, this is the first study to describe RV-associated insertional mutagenesis in mature T cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609016      PMCID: PMC3677306          DOI: 10.1038/mt.2013.67

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  43 in total

1.  T cell culture for gammaretroviral transfer.

Authors:  Sebastian Newrzela; Brandenburg Gunda; Dorothee von Laer
Journal:  Methods Mol Biol       Date:  2009

2.  Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Authors:  Sebastian Newrzela; Kerstin Cornils; Tim Heinrich; Julia Schläger; Ji-Hee Yi; Olga Lysenko; Janine Kimpel; Boris Fehse; Dorothee von Laer
Journal:  Mol Med       Date:  2011-07-27       Impact factor: 6.354

3.  Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.

Authors:  J Iqbal; D D Weisenburger; A Chowdhury; M Y Tsai; G Srivastava; T C Greiner; C Kucuk; K Deffenbacher; J Vose; L Smith; W Y Au; S Nakamura; M Seto; J Delabie; F Berger; F Loong; Y-H Ko; I Sng; X Liu; T P Loughran; J Armitage; W C Chan
Journal:  Leukemia       Date:  2010-11-05       Impact factor: 11.528

4.  Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.

Authors:  Inés Avedillo Díez; Daniela Zychlinski; Emanuele G Coci; Melanie Galla; Ute Modlich; Ricardo A Dewey; Adrian Schwarzer; Tobias Maetzig; Nonsikelelo Mpofu; Elmar Jaeckel; Kaan Boztug; Christopher Baum; Christoph Klein; Axel Schambach
Journal:  Mol Pharm       Date:  2011-08-31       Impact factor: 4.939

5.  Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.

Authors:  John Scholler; Troy L Brady; Gwendolyn Binder-Scholl; Wei-Ting Hwang; Gabriela Plesa; Kristen M Hege; Ashley N Vogel; Michael Kalos; James L Riley; Steven G Deeks; Ronald T Mitsuyasu; Wendy B Bernstein; Naomi E Aronson; Bruce L Levine; Frederic D Bushman; Carl H June
Journal:  Sci Transl Med       Date:  2012-05-02       Impact factor: 17.956

6.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Authors:  Alfonso Quintás-Cardama; Kris Vaddi; Phillip Liu; Taghi Manshouri; Jun Li; Peggy A Scherle; Eian Caulder; Xiaoming Wen; Yanlong Li; Paul Waeltz; Mark Rupar; Timothy Burn; Yvonne Lo; Jennifer Kelley; Maryanne Covington; Stacey Shepard; James D Rodgers; Patrick Haley; Hagop Kantarjian; Jordan S Fridman; Srdan Verstovsek
Journal:  Blood       Date:  2010-02-03       Impact factor: 22.113

7.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Authors:  Javeed Iqbal; Dennis D Weisenburger; Timothy C Greiner; Julie M Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; Shigeo Nakamura; Masao Seto; Jan Delabie; Francoise Berger; Florence Loong; Wing Y Au; Young-Hyeh Ko; Ivy Sng; James Olen Armitage; Wing C Chan
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

Review 8.  Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?

Authors:  F J T Staal; K Pike-Overzet; Y Y Ng; J J M van Dongen
Journal:  Leukemia       Date:  2008-09-04       Impact factor: 11.528

9.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.

Authors:  Stefan Stein; Marion G Ott; Stephan Schultze-Strasser; Anna Jauch; Barbara Burwinkel; Andrea Kinner; Manfred Schmidt; Alwin Krämer; Joachim Schwäble; Hanno Glimm; Ulrike Koehl; Carolin Preiss; Claudia Ball; Hans Martin; Gudrun Göhring; Kerstin Schwarzwaelder; Wolf-Karsten Hofmann; Kadin Karakaya; Sandrine Tchatchou; Rongxi Yang; Petra Reinecke; Klaus Kühlcke; Brigitte Schlegelberger; Adrian J Thrasher; Dieter Hoelzer; Reinhard Seger; Christof von Kalle; Manuel Grez
Journal:  Nat Med       Date:  2010-01-24       Impact factor: 53.440

10.  Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.

Authors:  S Eckerle; V Brune; C Döring; E Tiacci; V Bohle; C Sundström; R Kodet; M Paulli; B Falini; W Klapper; A B Chaubert; K Willenbrock; D Metzler; A Bräuninger; R Küppers; M-L Hansmann
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

View more
  13 in total

1.  T lymphocytes are not immune.

Authors:  Gianpietro Dotti
Journal:  Mol Ther       Date:  2013-06       Impact factor: 11.454

2.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

Review 3.  The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Authors:  Peter Braendstrup; Bruce L Levine; Marco Ruella
Journal:  Cytotherapy       Date:  2020-02-01       Impact factor: 5.414

4.  Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy.

Authors:  Axel Schambach; Michael Morgan; Boris Fehse
Journal:  Mol Ther       Date:  2021-08-24       Impact factor: 12.910

Review 5.  JAK-STAT in lipid metabolism of adipocytes.

Authors:  Dong Xu; Chunyan Yin; Sisi Wang; Yanfeng Xiao
Journal:  JAKSTAT       Date:  2013-12-06

6.  The EF-1α promoter maintains high-level transgene expression from episomal vectors in transfected CHO-K1 cells.

Authors:  Xiaoyin Wang; Zhongjie Xu; Zhengwei Tian; Xi Zhang; Danhua Xu; Qin Li; Junhe Zhang; Tianyun Wang
Journal:  J Cell Mol Med       Date:  2017-05-30       Impact factor: 5.310

7.  STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target.

Authors:  Erika Onozawa; Haruna Shibayama; Honami Takada; Ken-Ichi Imadome; Sho Aoki; Mayumi Yoshimori; Norio Shimizu; Shigeyoshi Fujiwara; Takatoshi Koyama; Osamu Miura; Ayako Arai
Journal:  Oncotarget       Date:  2018-07-24

Review 8.  Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy.

Authors:  Julia D Suerth; Verena Labenski; Axel Schambach
Journal:  Viruses       Date:  2014-12-05       Impact factor: 5.048

Review 9.  Progress and prospects for engineered T cell therapies.

Authors:  Waseem Qasim; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2014-06-17       Impact factor: 6.998

10.  Impact of Different Promoters on Episomal Vectors Harbouring Characteristic Motifs of Matrix Attachment Regions.

Authors:  Xiao-Yin Wang; Jun-He Zhang; Xi Zhang; Qiu-Li Sun; Chun-Peng Zhao; Tian-Yun Wang
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.